Regenxbio (RGNX) Other Accumulated Expenses (2014 - 2026)

Regenxbio's Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $757000.0 for Q4 2025.

• In Q4 2025, Other Accumulated Expenses rose 16.64% year-over-year to $757000.0; the TTM figure through Dec 2025 stood at $757000.0 (up 16.64% YoY), while the FY2025 annual figure was $757000.0, up 16.64% from the prior year.
• Other Accumulated Expenses for Q4 2025 stood at $757000.0, down from $929000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $999000.0 in Q1 2023, with the low at $122000.0 in Q1 2021.
• The 5-year median for Other Accumulated Expenses is $748000.0 (2022), against an average of $697500.0.
• Peak annual rise in Other Accumulated Expenses reached 363.44% in 2021, while the deepest fall reached 58.64% in 2021.
• Regenxbio's Other Accumulated Expenses stood at $744000.0 in 2021, then rose by 0.27% to $746000.0 in 2022, then tumbled by 38.61% to $458000.0 in 2023, then surged by 41.7% to $649000.0 in 2024, then climbed by 16.64% to $757000.0 in 2025.
• Business Quant data shows RGNX's Other Accumulated Expenses at $757000.0 in Q4 2025, $929000.0 in Q3 2025, and $736000.0 in Q2 2025.